PL3936130T3 - Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu - Google Patents

Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu

Info

Publication number
PL3936130T3
PL3936130T3 PL21178882.3T PL21178882T PL3936130T3 PL 3936130 T3 PL3936130 T3 PL 3936130T3 PL 21178882 T PL21178882 T PL 21178882T PL 3936130 T3 PL3936130 T3 PL 3936130T3
Authority
PL
Poland
Prior art keywords
valbenazine
treatment
dosage regimen
movement disorders
hyperkinetic movement
Prior art date
Application number
PL21178882.3T
Other languages
English (en)
Polish (pl)
Inventor
Christopher O'brien
Original Assignee
Neurocrine Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences, Inc. filed Critical Neurocrine Biosciences, Inc.
Publication of PL3936130T3 publication Critical patent/PL3936130T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL21178882.3T 2014-05-06 2015-05-06 Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu PL3936130T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06

Publications (1)

Publication Number Publication Date
PL3936130T3 true PL3936130T3 (pl) 2024-06-10

Family

ID=53264772

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21178882.3T PL3936130T3 (pl) 2014-05-06 2015-05-06 Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu
PL15724438T PL3139925T3 (pl) 2014-05-06 2015-05-06 Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15724438T PL3139925T3 (pl) 2014-05-06 2015-05-06 Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu

Country Status (24)

Country Link
US (3) US20170071932A1 (2)
EP (3) EP4389227A3 (2)
JP (4) JP6635945B2 (2)
KR (5) KR20240011255A (2)
CN (3) CN112741836A (2)
AU (1) AU2015256012B2 (2)
CA (1) CA2947736C (2)
CY (1) CY1125058T1 (2)
DK (2) DK3139925T3 (2)
ES (2) ES2976207T3 (2)
FI (1) FI3936130T3 (2)
HR (2) HRP20220025T1 (2)
HU (2) HUE057839T2 (2)
IL (1) IL248745B (2)
LT (2) LT3936130T (2)
MX (1) MX387625B (2)
NZ (1) NZ725826A (2)
PL (2) PL3936130T3 (2)
PT (2) PT3936130T (2)
RS (2) RS62782B1 (2)
RU (1) RU2753740C2 (2)
SI (2) SI3139925T1 (2)
SM (2) SMT202400199T1 (2)
WO (1) WO2015171802A1 (2)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61645B1 (sr) * 2015-10-30 2021-04-29 Neurocrine Biosciences Inc Valbenazin ditozilat i njihovi polimorfi
JP6869988B2 (ja) 2015-12-23 2021-05-12 ニューロクライン バイオサイエンシーズ，インコーポレイテッド （Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
US10442800B2 (en) 2016-06-29 2019-10-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of NBI-98854, preparation method and use thereof
WO2018102673A1 (en) * 2016-12-02 2018-06-07 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
US10703750B2 (en) 2017-01-10 2020-07-07 Sandoz Ag Crystalline valbenazine free base
CA3051830A1 (en) 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
EP3585787A1 (en) 2017-02-27 2020-01-01 Sandoz AG Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CN110678181A (zh) * 2017-04-01 2020-01-10 阿德普蒂奥制药有限公司 (+)-α-二氢丁苯那嗪在治疗运动障碍中的用途
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
AU2018241940B2 (en) * 2017-04-01 2023-09-28 Adeptio Pharmaceuticals Limited Dihydrotetrabenazine for use in the treatment a movement disorder
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
SG11202004165UA (en) * 2017-11-08 2020-06-29 Yuhua Li Esters of dihydrotetrabenazine
JP7212958B2 (ja) 2017-12-26 2023-01-26 ▲蘇▼州科睿思制▲葯▼有限公司 バルベナジントシル酸塩の結晶形及びその製造方法並びに用途
CA3097189A1 (en) * 2018-04-25 2019-10-31 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
AU2019287524A1 (en) 2018-06-14 2020-12-24 Neurocrine Biosciences, Inc. VMAT2 inhibitor compounds, compositions, and methods relating thereto
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
MA55893A (fr) * 2019-05-09 2022-03-16 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081929B1 (en) * 2006-11-08 2013-01-09 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
EP2083744A4 (en) * 2006-11-09 2013-08-28 Univ New York DEGRADED GLASS / ZIRCONIUM / GLASS STRUCTURES FOR DAMAGE-RESISTANT DENTAL AND ORTHOPEDIC CERAMIC PROSTHESES
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
WO2011019956A2 (en) 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
CA2972242A1 (en) 2008-09-18 2010-04-22 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP3351247A1 (en) * 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
EP4345100A3 (en) 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN106061506A (zh) * 2014-02-07 2016-10-26 纽罗克里生物科学有限公司 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途

Also Published As

Publication number Publication date
IL248745A0 (en) 2017-01-31
AU2015256012B2 (en) 2020-07-23
RS62782B1 (sr) 2022-01-31
SI3936130T1 (sl) 2024-05-31
CN106456629A (zh) 2017-02-22
CA2947736C (en) 2023-04-18
RU2016147523A (ru) 2018-06-08
DK3936130T3 (da) 2024-03-25
KR20220140647A (ko) 2022-10-18
HUE066361T2 (hu) 2024-07-28
RU2753740C2 (ru) 2021-08-23
CA2947736A1 (en) 2015-11-12
EP3139925B1 (en) 2021-12-01
LT3936130T (lt) 2024-04-25
US20200101063A1 (en) 2020-04-02
MX387625B (es) 2025-03-18
PT3139925T (pt) 2022-01-26
KR20250029267A (ko) 2025-03-04
KR20160147044A (ko) 2016-12-21
CY1125058T1 (el) 2023-06-09
HRP20220025T1 (hr) 2022-04-01
EP3139925A1 (en) 2017-03-15
EP3936130A1 (en) 2022-01-12
EP3936130B1 (en) 2024-02-14
US20210196702A1 (en) 2021-07-01
PT3936130T (pt) 2024-04-17
RS65359B1 (sr) 2024-04-30
ES2976207T3 (es) 2024-07-26
US20170071932A1 (en) 2017-03-16
CN112741836A (zh) 2021-05-04
HUE057839T2 (hu) 2022-06-28
JP2024153782A (ja) 2024-10-29
HRP20240459T1 (hr) 2024-06-21
SMT202200193T1 (it) 2022-07-21
FI3936130T3 (fi) 2024-04-23
MX2016014429A (es) 2017-04-06
EP4389227A3 (en) 2024-09-04
NZ725826A (en) 2023-05-26
LT3139925T (lt) 2022-01-25
JP2019218407A (ja) 2019-12-26
WO2015171802A1 (en) 2015-11-12
JP2017514850A (ja) 2017-06-08
RU2016147523A3 (2) 2018-12-28
AU2015256012A1 (en) 2016-11-24
ES2904526T3 (es) 2022-04-05
KR20240011255A (ko) 2024-01-25
SMT202400199T1 (it) 2024-07-09
EP4389227A2 (en) 2024-06-26
JP2021191799A (ja) 2021-12-16
IL248745B (en) 2022-07-01
SI3139925T1 (sl) 2022-04-29
KR20200133003A (ko) 2020-11-25
CN112741835A (zh) 2021-05-04
DK3139925T3 (da) 2021-12-20
JP6635945B2 (ja) 2020-01-29
PL3139925T3 (pl) 2022-03-21

Similar Documents

Publication Publication Date Title
PL3936130T3 (pl) Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu
IL247452A0 (en) Compounds for treatment of complement mediated disorders
IL256166B (en) Compounds for use in treating neuromuscular disorders
IL256175A (en) Using exosomes to treat the disease
LT3206715T (lt) Kanabidiolio naudojimas tuberozinės sklerozės komplekso gydymui
HUE059662T2 (hu) Eljárás terápiás immunsejtek hatékonyságának fokozására
LT3882250T (lt) Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui
MA39483A (fr) Agents thérapeutiques cibles
DK3215607T3 (da) Phagterapi
GB201410816D0 (en) Therapeutic agents
IL249502B (en) New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
DK3363428T3 (da) Perfusionsdoseringsform
IL251904A0 (en) Apilimod for use in the treatment of melanoma
PL3978074T3 (pl) Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1
GB201410815D0 (en) Therapeutic agents
DK3137126T3 (da) Medicinske indretninger med ikke-ensartede coatinger med henblik på forbedret ekkogenicitet
GB201410817D0 (en) Therapeutic agents
DK3215223T3 (da) Buprenorphindoseringsskemaer
DK3126791T3 (da) Doseringsanordning
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
HUE046209T2 (hu) Kompozíció porckoronggal összefüggõ fájdalom kezelésében történõ alkalmazásra
DE112015001144A5 (de) Therapievorrichtung
IL249374A0 (en) Pharmaceutical administration forms
TH1601003393A (th) รูปแบบปริมาณที่ให้ทางเภสัชกรรม